GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rapid Dose Therapeutics Corp (XCNQ:DOSE) » Definitions » Debt-to-Revenue

Rapid Dose Therapeutics (XCNQ:DOSE) Debt-to-Revenue : 1.30 (As of Nov. 2024)


View and export this data going back to 2010. Start your Free Trial

What is Rapid Dose Therapeutics Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Rapid Dose Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Nov. 2024 was C$0.00 Mil. Rapid Dose Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Nov. 2024 was C$2.61 Mil. Rapid Dose Therapeutics's annualized Revenue for the quarter that ended in Nov. 2024 was C$2.01 Mil. Rapid Dose Therapeutics's annualized Debt-to-Revenue for the quarter that ended in Nov. 2024 was 1.30.


Rapid Dose Therapeutics Debt-to-Revenue Historical Data

The historical data trend for Rapid Dose Therapeutics's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rapid Dose Therapeutics Debt-to-Revenue Chart

Rapid Dose Therapeutics Annual Data
Trend Sep15 Sep16 Sep17 Sep18 Feb19 Feb20 Feb21 Feb22 Feb23 Feb24
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12.11 2.73 0.67 2.24 2.20

Rapid Dose Therapeutics Quarterly Data
Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.94 2.91 1.61 1.26 1.30

Competitive Comparison of Rapid Dose Therapeutics's Debt-to-Revenue

For the Biotechnology subindustry, Rapid Dose Therapeutics's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rapid Dose Therapeutics's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rapid Dose Therapeutics's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Rapid Dose Therapeutics's Debt-to-Revenue falls into.



Rapid Dose Therapeutics Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Rapid Dose Therapeutics's Debt-to-Revenue for the fiscal year that ended in Feb. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0.123 + 2.125) / 1.02
=2.20

Rapid Dose Therapeutics's annualized Debt-to-Revenue for the quarter that ended in Nov. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0 + 2.61) / 2.008
=1.30

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Nov. 2024) Revenue data.


Rapid Dose Therapeutics Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Rapid Dose Therapeutics's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Rapid Dose Therapeutics Business Description

Traded in Other Exchanges
Address
1121 Walkers Line, Unit 3, Burlington, ON, CAN, L7N 2G4
Rapid Dose Therapeutics Corp is a Canadian biotechnology company revolutionizing drug delivery through innovation. The company's flagship product QuickStrip is a thin, orally dissolvable film, that can be infused with an infinite list of active ingredients (nutraceuticals, pharmaceuticals, vaccines, and cannabis) that are delivered quickly into the bloodstream resulting in rapid onset of the active ingredient.
Executives
Mark Upsdell Director
Brian Howlett Director

Rapid Dose Therapeutics Headlines

No Headlines